Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease

[1]  S. Lincoln,et al.  Transcript levels in plasma contribute substantial predictive value as potential Alzheimer's disease biomarkers in African Americans , 2022, EBioMedicine.

[2]  K. Blennow,et al.  Plasma biomarkers for Alzheimer’s Disease in relation to neuropathology and cognitive change , 2022, Acta Neuropathologica.

[3]  K. Blennow,et al.  Plasma p‐tau231, p‐tau181, PET Biomarkers, and Cognitive Change in Older Adults , 2022, Annals of neurology.

[4]  Lin F. Yang,et al.  Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019 , 2022, The Lancet. Public health.

[5]  W. M. van der Flier,et al.  Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231 , 2021, Alzheimer's Research & Therapy.

[6]  M. Greicius,et al.  Plasma Biomarkers of Tau and Neurodegeneration During Major Cardiac and Noncardiac Surgery. , 2021, JAMA neurology.

[7]  O. Hansson,et al.  Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays , 2021, Neurology.

[8]  C. Jack,et al.  Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. , 2021, JAMA neurology.

[9]  K. Blennow,et al.  Association of plasma P-tau181 with memory decline in non-demented adults , 2021, Brain communications.

[10]  O. Hansson,et al.  Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects , 2021, Brain : a journal of neurology.

[11]  M. Carrillo,et al.  The strategic biomarker roadmap for the validation of Alzheimer’s diagnostic biomarkers: methodological update , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  K. Blennow,et al.  The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  K. Blennow,et al.  Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology , 2021, Acta Neuropathologica.

[14]  K. Blennow,et al.  Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease , 2021, JAMA neurology.

[15]  Valerie A. Carr,et al.  Association of CSF Biomarkers With Hippocampal-Dependent Memory in Preclinical Alzheimer Disease , 2021, Neurology.

[16]  M. Carrasquillo,et al.  Plasma Biomarkers of Alzheimer’s Disease in African Americans , 2020, Journal of Alzheimer's disease : JAD.

[17]  K. Blennow,et al.  Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected , 2020, EMBO molecular medicine.

[18]  K. Blennow,et al.  Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. , 2020, JAMA.

[19]  K. Blennow,et al.  Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline , 2020, Acta Neuropathologica.

[20]  J. Trojanowski,et al.  Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative , 2020, Molecular Psychiatry.

[21]  K. Blennow,et al.  Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum , 2020, medRxiv.

[22]  Nick C Fox,et al.  Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer’s disease: a longitudinal cohort study , 2020, Molecular Psychiatry.

[23]  K. Blennow,et al.  Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts , 2020, The Lancet Neurology.

[24]  K. Blennow,et al.  Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia , 2020, Nature Medicine.

[25]  L. Tian,et al.  Soluble TREM2 is elevated in Parkinson's disease subgroups with increased CSF tau. , 2020, Brain : a journal of neurology.

[26]  Valerie A. Carr,et al.  Hippocampal and cortical mechanisms at retrieval explain variability in episodic remembering in older adults , 2020, bioRxiv.

[27]  C. Jack,et al.  Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography , 2018, Alzheimer's & Dementia.

[28]  Linda J. C. van Waalwijk van Doorn,et al.  Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry , 2017, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[29]  P. Snyder,et al.  Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic , 2017, Alzheimer's & Dementia.

[30]  C. Jack,et al.  Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria , 2016, Alzheimer's & Dementia.

[31]  Keith A. Johnson,et al.  The Evolution of Preclinical Alzheimer’s Disease: Implications for Prevention Trials , 2014, Neuron.

[32]  Cindee M. Madison,et al.  Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. , 2009, Brain : a journal of neurology.

[33]  J. Cummings,et al.  The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.

[34]  K. Blennow,et al.  Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization , 2000, Neuroscience Letters.

[35]  P. Cohen,et al.  Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein. , 1994, The Biochemical journal.

[36]  R. Castellani,et al.  Alzheimer disease. , 2010, Disease-a-month : DM.

[37]  K. Blennow,et al.  Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies , 2006, Clinical chemistry and laboratory medicine.

[38]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..